CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. - Test2 - elhamkhani - TriplyDB

CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib.

CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib.

http://www.wikidata.org/entity/Q40040623

about

Cancer-selective targeting of the NF-κB survival pathway with GADD45β/MKK7 inhibitors Computational Approaches for the Discovery of Human Proteasome Inhibitors: An Overview Salvage therapies in relapsed and/or refractory myeloma: what is current and what is the future?Novel strategies to target the ubiquitin proteasome system in multiple myeloma The 26S proteasome is a multifaceted target for anti-cancer therapies DangER: protein ovERload. Targeting protein degradation to treat myeloma Boron chemicals in diagnosis and therapeutics Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S β5-subunit Incorporation of Non-natural Amino Acids Improves Cell Permeability and Potency of Specific Inhibitors of Proteasome Trypsin-like Sites Homopiperazine derivatives as a novel class of proteasome inhibitors with a unique mode of proteasome binding Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling Trial Watch: Proteasomal inhibitors for anticancer therapy Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma.Synthesis and biological evaluation of naphthoquinone analogs as a novel class of proteasome inhibitors The effects of proteasome inhibitors on bone remodeling in multiple myeloma.Bcl-2 antagonists interact synergistically with bortezomib in DLBCL cells in association with JNK activation and induction of ER stress.Discovery of a potent and highly β1 specific proteasome inhibitor from a focused library of urea-containing peptide vinyl sulfones and peptide epoxyketones.The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumors Proteasome inhibition and its therapeutic potential in multiple myeloma Nature of pharmacophore influences active site specificity of proteasome inhibitors.Advances in and applications of proteasome inhibitors Molecular basis of differential sensitivity of myeloma cells to clinically relevant bolus treatment with bortezomib.Proteasome inhibitors in the treatment of multiple myeloma Novel therapeutics in multiple myeloma.Oxadiazole-isopropylamides as potent and noncovalent proteasome inhibitors.New insights, recent advances, and current challenges in the biological treatment of multiple myeloma.Gene expression profiling predicts the development of oral cancer.Proteasome inhibitors in cancer therapy Antitumor effects of tyropeptin-boronic acid derivatives: New proteasome inhibitors.Proteasome inhibitor patents (2010 - present).The 26S proteasome complex: an attractive target for cancer therapy The ubiquitin-proteasomal system is critical for multiple myeloma: implications in drug discovery The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells.Emodin potentiates the antiproliferative effect of interferon α/β by activation of JAK/STAT pathway signaling through inhibition of the 26S proteasome Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials The novel orally active proteasome inhibitor K-7174 exerts anti-myeloma activity in vitro and in vivo by down-regulating the expression of class I histone deacetylases.Targeting ubiquitination for cancer therapies.Role of ubiquitin ligases and the proteasome in oncogenesis: novel targets for anticancer therapies.Inhibitors of the immunoproteasome: current status and future directions Pediatric developmental therapies: interesting new drugs now in early-stage clinical trials.

P2860

Q24305602-852FF17D-D663-44A4-B06D-E9B5218588FB Q26738752-BBC3A370-268F-4A73-87D8-82BE75CE2A62 Q26740359-45CC7BD6-6845-4B98-81DB-F8204C751301 Q26773246-6B2D46DF-5374-405F-AD23-AEC9C60B84A1 Q26795764-23A36A32-9FFA-46E8-8D80-E408A3A06F60 Q26825417-692C0507-AB68-43CD-B652-44458A6FEDAA Q27006075-291DF24D-3830-4FDD-A623-A430D829F5FE Q27663486-43684579-CB91-4DB4-913D-9530BB5D8B79 Q27675903-98A2F467-B6DE-45D2-B0AE-AEDA143506D5 Q27677425-04C5D160-A387-4F0B-A027-3903059C0C1B Q28082335-82E1C1EF-FA04-4B27-A026-0037E9FD5B2E Q28082910-88E72ED1-DA75-48A3-AABD-F0567E6F094B Q33438839-CFD9636B-C095-4A64-97A3-2483C621802A Q33629972-F8E962A6-84F0-4048-BA69-3317492E98DE Q33918020-526C1183-8950-44AF-83EC-F4DB072F6584 Q33989217-75D6EB6F-30FE-4D8D-8F7D-01E451D8D07B Q34079904-307596E8-60DF-45DF-8AFC-56325826FDC3 Q34218976-3FBF36C9-0F24-4F1B-BAB4-34D7963B5554 Q34343036-6D5C9E5B-5491-4183-8FAA-B07627BFBF00 Q34401062-2DDC3205-441E-420E-B25F-2C8188C062AA Q34594744-3FBE40DE-4EA8-4E39-AE61-A5DFCA5BD424 Q34608271-B62DC334-7CB9-45BD-BE49-D804655F3BF4 Q34611676-BC5041BB-B3BB-4F50-9664-92FE0C2F2A4B Q34637538-87AABD49-E5B9-46DE-8231-B123DEE08646 Q34644848-181B74FD-B447-4208-BAAD-3794F06F9674 Q34773850-1A06762E-2390-4DC0-A70C-1980AFD84CC0 Q34782013-EC6262AE-8136-498A-B4BF-AB2FD0ACE49E Q34939959-BFA5B6FE-5A27-4F54-82CC-D6D03FDC38FA Q35052044-162BF522-7F7A-417F-83F2-9A9623C557DE Q35085938-28B28474-3E3A-4F9F-83B4-6AB63253FC02 Q35624079-9F767ED9-D6A8-4F76-9637-DB38474AB242 Q35824929-2231BBA9-8CED-4430-97BE-A30CD91642AE Q36115692-B246EA06-58FD-4E2B-89B4-06BE18E6F794 Q36782542-836E0BF0-4C92-4FDD-9E1E-ACC9DD0E974A Q37017342-73A7FAF2-0D2B-4CDF-85C5-BADF9BD335B2 Q37132187-12EE7BCC-70B1-41B2-BF1D-DC303B3D7657 Q37158445-06B3091B-A1CD-416C-BFD4-86F0A7050195 Q37252274-64374D44-53CF-4553-BB40-62580FEC904B Q37292307-0BB663E2-1830-48A7-BCF9-D5C913A15E22 Q37301320-396DFD25-A9BD-4C5F-911E-25FBF1C3F66F

P2860

CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib.

http://www.wikidata.org/entity/Q40040623

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

CEP-18770: A novel, orally act ...... e competitive with bortezomib.

@en

type

label

CEP-18770: A novel, orally act ...... e competitive with bortezomib.

@en

prefLabel

CEP-18770: A novel, orally act ...... e competitive with bortezomib.

@en

P1433

Q40040623-07887266-BB15-429E-B40E-6C8F7D9C5C9B

P1476

Q40040623-36241C5E-C77F-4B19-B308-1B4A7D933013

P2093

Q40040623-1C971085-B3DB-4A07-98FE-4DFE9003BC5B

Q40040623-1F87C82C-B667-46C1-84C1-726FA94CFF54

Q40040623-24ABACE6-7B46-45E9-8C36-F49BE0236337

Q40040623-2558CBA3-1A64-46D1-8640-51FFD4BE85B3

Q40040623-4B6E2318-280B-4409-8C5A-C82D8CEF96D4

Q40040623-4D7E24F5-20E2-4506-A7FA-A4E83F1C686D

Q40040623-6EF1908F-BB10-4EE4-801C-2C2AC276A6B2

Q40040623-6FDDDE96-11F4-4D06-99CC-00D61EC9928A

Q40040623-73509916-3EDA-44FC-AEB5-4940ED6EA7D0

Q40040623-7CEBA26E-66BF-453E-8D98-1BF9BB761E8E

P304

Q40040623-5094C853-E683-4E30-B598-09900395BA1A

P31

Q40040623-F948139D-ED37-411A-B30B-A0F19E4AF4EA

P356

Q40040623-0212EB39-33C4-44B4-B1E8-617FEA85BF82

P407

Q40040623-53305C4A-C24F-4D75-8BCF-A326D072475E

P433

Q40040623-DFA0EC84-2B19-4529-8B34-6A9340A69414

P478

Q40040623-414B0F2C-9781-4880-ADF5-2B3F7982A3EB

P50

Q40040623-06183988-9CA9-4B2E-8BC4-FEBCE5301566

Q40040623-2F5E88CF-A6A7-4F6C-8627-0539FB7CE5C0

Q40040623-3EF27871-23CF-4390-87EF-A31F22A353D9

Q40040623-500BA411-7BA5-42B7-9EF1-FC86A6E7D702

Q40040623-620CFE2E-F5F7-4B37-8AFF-048DBA073B5F

Q40040623-8749427D-318D-4B71-BC30-E7ABB6E518D1

Q40040623-8B792EF0-2419-43E3-A658-FB23B00A224F

Q40040623-B7B16A49-C12D-4B66-BF1B-E6E0EA63C040

Q40040623-C27E6587-8FF1-4A14-8675-4E9550A359CE

Q40040623-D3806872-BA62-48B8-8170-3C95F99402E5

P577

Q40040623-EDFA7185-95DF-47A0-9F3B-A36E66F51F9B

P5875

Q40040623-9D251EF0-1848-450D-9308-2A9AFF917305

P698

Q40040623-A4A695C6-C22F-4E6E-8B3F-8CE0091B1330

P921

Q40040623-C088BEB1-6F18-4F53-BF0E-858FF8DE24DC

P356

BLOOD-2007-07-100651

P1433

P1476

CEP-18770: A novel, orally act ...... e competitive with bortezomib.

@en

P2093

Alberto Bernareggi

http://www.w3.org/2001/XMLSchema#string

Bruce Ruggeri

http://www.w3.org/2001/XMLSchema#string

Cecilia Allievi

http://www.w3.org/2001/XMLSchema#string

Celia Berkers

http://www.w3.org/2001/XMLSchema#string

Dario Ferrero

http://www.w3.org/2001/XMLSchema#string

Gabriella Pezzoni

http://www.w3.org/2001/XMLSchema#string

Giorgio Inghirami

http://www.w3.org/2001/XMLSchema#string

Giulia Costa

http://www.w3.org/2001/XMLSchema#string

Hugh Zhao

http://www.w3.org/2001/XMLSchema#string

Ivan Strepponi

http://www.w3.org/2001/XMLSchema#string

P304

2765-2775

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2007-07-100651

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

111

http://www.w3.org/2001/XMLSchema#string

P50

Benedetta Bussolati

Giovanni Camussi

Giorgio Inghirami

Massimo Massaia

P577

2007-12-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5791435

http://www.w3.org/2001/XMLSchema#string

P698

18057228

http://www.w3.org/2001/XMLSchema#string

P921